Bionano Announces Presentation of Optical Genome Mapping (OGM) Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting
- Dr. Alka Chaubey, chief medical officer at Bionano, will host a sponsored vendor panel presentation on the integration of OGM for clinical research in cancer, featuring cancer genomics experts Dr.
Ravindra Kolhe, Augusta University, Dr. Yassmine Akkari, Nationwide Children’s Hospital, Dr. Susan Crocker, Kingston Health Sciences Centre/ Queen’s University, and Dr. Sachin Jadhav, HCG Network
- Thirteen scientific platform and poster presentations will illustrate the application of Bionano’s OGM workflow in research areas including solid tumors, hematological malignancies, leukemia and basophilia
- Bionano will introduce the latest products in the company’s OGM workflow to conference attendees, including Ionic G2 kits for the Ionic® Purification System, featuring new chemistry for nucleic acid extraction from formalin-fixed paraffin-embedded (FFPE) and tumor tissue, and VIA™ software for hematological malignancies, which offers a simple and integrated workflow for visualization, interpretation and reporting across OGM, microarray and next-generation sequencing (NGS) data
- Bionano is a Diamond Sponsor at the conference, and will host conference attendees, customers, KOLs, and VIPs from the genomics and cytogenetics communities at an evening reception
CGC’s annual meeting brings together industry, medical, and academic professionals to discuss advances in clinical genomics for oncology research. CGC conference sessions will be held
As part of a sponsored spotlight panel, Bionano’s chief medical officer, Dr.
Thirteen separate scientific presentations highlighting OGM as a novel technique in cancer research will be given at the conference. Presenters from Bionano,
In addition, three posters featuring results from OGM applications in cytogenetics and cancer research will be presented at the conference.
Scientific presentations from Bionano and collaborators include:
|Session 1: Applications of Emerging Technologies in Clinical Genomics||Application of optical genome mapping to identify samples with homologous recombination deficiency||Hastie, A.|
|Speed Abstracts Session I: Use of Different Molecular Techniques to Diagnose Cancer||Evaluation of Hi-C versus optical genome mapping for diagnosing constitutional genomic structural variants
|Session 4: Clinical Utility of Genomic Testing for Identification and Potential for Therapy Selection in Solid Tumors||Optical genome mapping reveals new insights into ZFTA fusion in supratentorial ependymomas
|Speed Abstracts Session II||Analytical validation of an optical genome mapping assay for the detection of structural variation in hematologic malignancies as a lab-developed test||Sahoo, T.|
|Speed Abstracts Session II||Clinical utility of optical genome mapping: comparison with standard cytogenomics work-up for hematological malignancies||Toruner, G.|
|Sponsored Session||Unleashing Genomic Insights That Matter with Optical Genomic Mapping: An Interactive Panel Discussion||Chaubey A., Kolhe R., Akkari Y., Crocker S., Jadhav S.|
|Session 6: Integration of Novel Technologies in the
||Optical genome mapping identifies additional cytogenetic abnormalities in patients with hematologic malignancies
|Spotlight Symposium||ISCN 2024 update including a preview of the new genomic mapping nomenclature
|Session 8: Value of Novel Technologies for the Identification of Clonal Aberrations Different from Standard of Care Findings in Hematologic Malignancies||Optical genome mapping in hematological malignancy: clinical outcomes in a 2-year follow-up retrospective study
|Session 9: Applications of Emerging Technologies in Clinical Genomics||Rare SRY-positive derivative X chromosome in female fetus with apparently normal development
|Session 9: Applications of Emerging Technologies in Clinical Genomics||A novel method for detection of loss of heterozygosity using B-allele frequency from optical genome mapping data||Raksi, A.|
The following scientific posters from Bionano and collaborators will be on display
|Novel complex translocation causing a PDGFRA-PRKG2 fusion identified by optical genome mapping in myeloid neoplasm with basophilia||Rao, S.|
|Atypical BCR-ABL1 rearrangements identified by optical genome mapping in patients with chronic myeloid leukemia||Sahoo, T.|
|Optical genome mapping for detection of biomarkers in residual disease monitoring research of hematologic malignancies||Yu, J.|
“Bionano is pleased to participate in the CGC conference this year, with a variety of presentations and posters covering the utility of our solutions for cancer research applications. We are excited to share our latest product advancements with CGC conference attendees, including VIA, our new software that offers a simple and integrated workflow for visualization, interpretation and reporting for data types including OGM, next-generation sequencing and microarrays. VIA also features a heme malignancy workflow, including curated resources that represent guideline-based targets applicable to hematological disease, which we believe will make the product particularly relevant for cancer researchers,” commented
More details on the conference can be found here: https://bionano.com/cgc2023/.
Bionano is a provider of genomic analysis solutions that can help reveal answers to challenging genetic questions. Our mission is to transform the way the world sees the genome through optical genome mapping (OGM). Our OGM solutions allow scientists and clinical researchers the ability to see and discover structural variations in a way unmatched by traditional cytogenetic techniques. Our products additionally include an industry-leading, platform-agnostic software solution, which integrates OGM, next-generation sequencing and microarray data in one consolidated view, and nucleic acid extraction and purification solutions using proprietary isotachophoresis technology. Our
Unless specifically noted otherwise, Bionano products are provided for Research Use Only. Not for use in diagnostic procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “potential,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the potential of our OGM workflows or other genomic solutions to be useful in research applications such as solid tumors, hematological malignancies, leukemia and basophilia; the ability of our OGM workflows and other genomic solutions to offer new insights and address critical gaps left unanswered by other genome analysis products; OGM’s utility in research, development, and manufacturing processes for monitoring genomic integrity and off-target effects in cell lines and its potential to improve the quality, safety, and overall risk profile of next-generation therapy development and manufacturing; the utility of OGM for research in the areas reported in the presentations given and the posters made available at the CGC annual meeting; the utility, relevance and benefits of our latest products, including Ionic G2 kits for the Ionic Purification System and VIA software, for cancer researchers; and the growth and adoption of OGM for use in monitoring genomic integrity and off-target effects in cell lines. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: global and macroeconomic events, such as recent and potential bank failures, potential resurgences of COVID-19 and the ongoing
+1 (858) 888-7610
+1 (858) 888-7625
Source: Bionano Genomics